Schizophrenia is a severe mental disorder that causes disruptions in "thought processes, perceptions, emotional responsiveness, and social interactions," according to the National Institute of Mental Health. While it may not be a prevalent condition, it does affect roughly 1 in every 200 individuals worldwide. Typical treatment options include counselling and pharmaceuticals. The future of how this mental disorder is treated, however, could be much different.

A recent study from the University of New Mexico concluded that phytocannabinoid therapies could be a useful treatment option for schizophrenia. The report states "emerging research suggests that Cannabis can be used as a treatment for schizophrenia within a broader etiological perspective that focuses on environmental, autoimmune, and neuroinflammatory causes of the disorder, offering a fresh start and newfound hope for those suffering from this debilitating and poorly understood disease."

In particular, a phytocannabinoid by the name of Cannabidiol or CBD is proving to offer significant benefits for patients with this disorder by targeting the endocannabinoid system and the inflammatory issues that this disorder presents.

Schizophrenia, like many mental disorders, not only affects those who are diagnosed with the disease but also their friends, family, and loved ones. Schizophrenia causes many psychotic symptoms including, but not limited to, cognitive impairment, delusions, hallucinations, unusual manners of thinking, reduced motivation, motor impairment, and difficulty in social relationships. All of these symptoms, as you could probably imagine, could cause tension, stress, and other issues between the patient and those around them.

Being that cannabis is a natural plant and has the ability to offer patients with Schizophrenia effective relief, it could be an excellent alternative for thousands of individuals who live with this condition daily. As more states and countries worldwide free this natural plant from the harmful arms of prohibition, we are bound to see more studies surrounding cannabis and its effectiveness in providing relief for schizophrenia patients.

  Posted: Wednesday, October 31st, 10:00am 15 days ago
Profile PictureWritten By: Ashley Priest

Ashley is a freelance cannabis writer and the co-owner of CannaLance. Her passion for sharing education and truth surrounding cannabis stems from a personal loss. Ashley has always had an elevated relationship with cannabis but it wasn't until 2015 that she turned that passion and relationship into a career as a cannabis writer.

Roottie keeps me up to date on all things cannabis. From new uses for CBD to opportunities that affect my business, Roottie is my source. Roottie provides informative and entertaining information that is up to date and accessible. -Karla Watson - Tact HR Services

Break It Up